Mechanisms involved in metastasis enhanced by inflammatory mediators by Männel, D. N. et al.
Circulatory Shock 44:9-13 (1994) 
Mechanisms Involved in Metastasis 
Enhanced by Inflammatory Mediators 
Daniela N. Marmel, Peter Orosz, Michael Hafner, and Werner Falk 
Tumorimmunology, Departments of Pathology (D.N.M., M.H.) and Internal Medicine I 
(W.F.), University of Regensburg, Regensburg; German Cancer Research Centre, 
Division of Cellular Immunology, Heidelberg (P.O.), Germany 
The enhancement of tumor metastasis by concurrent inflammatory processes is mainly due 
to the cytokines TNF and IL-1. In the case of TNF this effect is not restricted to metastasis 
models as measured by in vivo colony formation but also found in experimental model 
systems of spontaneous metastasis. Direct effects on the tumor cells or interference with the 
host NK cell system did not seem to account for the observed TNF effect. Experimental 
evidence from different test systems rather points to TNF- or IL-1-induced enhanced adhe-
sion of tumor cells to the endothelial cell layer as the underlying mechanism. Blocking of 
integrin-matrix interactions with monoclonal antibodies or competing peptides inhibited tu-
mor cell adhesion to endothelioma cells in vitro and lung colony formation of tumor cells 
in Vivo. ©1994 Wiley-Liss, Inc. 
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INTRODUCTION 
The process of metastasis is a multistep event through 
which tumor cells have to pass in order to colonize a 
target tissue. Deriving from a primary tumor, they are 
bound to get into the blood or lymph circulation and later 
to adhere to the endothelial cell layer within the target 
organ of metastasis. In order to get some insight at the 
molecular level in the complexity of the many events of 
cell-cell interaction taking place, experimental systems 
have to be established which dissect the entire event of 
metastasis into individual steps. The endeavour to dissect 
such a complex series of interactions by using simplified 
assay systems bears the danger of concentrating on 
epiphenomena or artifacts which might be of no rele-
vance to the in vivo situation. Therefore, the findings 
from in vitro assays or from simplified in vivo experi-
mental systems have to be validated in the more complex 
in vivo experimental systems of spontaneous metastasis 
which are closer to the clinical situation or best in biop-
sies from clinical studies. 
Since inflammatory cytokines like TNF. IL-1, I F N 7 , 
etc. became available for clinical use, attempts have been 
made to utilize their antitumoral or immunomodulatory 
capacity for cancer therapy. These cytokines, however, 
due to their pleiotropic actions, also had the potential to 
exert effects adverse to the attempted goal of anticancer 
efficacy. Accordingly, several investigators have re-
ported that the usage of inflammatory cytokines in vivo 
might actually enhance metastasis [1-5]. In order to clar-
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if y the basis for these observations, we established 
in vitro and in vivo adhesion assays for different tumor 
cells on endothelial cell layers to evaluate the contribu-
tion of some of the TNF-modulated molecules to the 
tumor cell-endothelial cell interactions. Furthermore, we 
intended to find out whether the observations made under 
these relatively artificial conditions have impact on ex-
perimental or spontaneous metastasis in mouse models. 
MATERIALS AND METHODS 
Mice 
Female mice, 5-7 weeks of age were obtained from the 
Institut für Versuchstierforschung (Hannover, Germany) 
or from Charles River Wiga GmbH (Sulzfeld, Germany). 
The NK-deficient beige mice on a C57B1/6 background 
were a generous gift from Dr. H . Mossmann, Max-
Planck-Institut für Immunbiölogie (Freiburg, Germany). 
The animals were kept in the central animal facility of the 
German Cancer Research Centre under specific-patho-
gen-free conditions or at the animal facility of the Univer-
sity Clinic of Regensburg throughout the experiments. 
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Tumor Cells 
CSFl is a methylcholanthrene-induced fibrosarcoma 
cell line of C3H/HeN mouse origin. ESb is a highly 
metastatic subline of the methylcholanthrene-induced 
DBA/2 lymphoma L5178YE (Eb) [6]. L929 is a TNF-
sensitive mouse fibrosarcoma cell line. Cells were cul-
tured in RPMI 1640 supplemented with 10% heat-inacti-
vated FCS, 5 mM Hepes, 100 IU/ml penicillin, 0.1 
mg/ml streptomycin (all from Gibco-BRL, Eggenstein, 
Germany). The mouse bEnd3 endothelioma cells [7] 
were kindly provided by Dr. W. Risau and were main-
tained in DMEM with high glucose (Gibco-BRL) con-
taining 10% FBS (Gibco-BRL, low endotoxin). For ad-
hesion assays cells were transfered to Labtek glass 
chamber slides (Nunc) and grown to confluency. Al l cells 
were kept at 37°C, 5% C 0 2 , and 90% humidity in air. 
Reagents 
Recombinant human tumor necrosis factor (rhTNF) 
with a specific activity of 9 x 106U/mg and recombinant 
mouse tumor necrosis factor (rmTNF) with a specific 
activity of 8 X 107 U/mg were generous gifts from 
BASF/Knoll AG (Ludwigshafen, Germany). TNF was 
injected i.p. at different time points as indicated in the 
legends. The rat anti-mouse TNF mAb V1Q was purified 
and used as recently described [8]. Polyclonal rat IgG and 
LPS (from Salmonella minnesota) were purchased from 
Sigma Chemical Co. (St. Louis, MO). 
Quantification of Metastases 
The nonadherent tumor cells were washed twice and 
resuspended in HBSS. Either 2 x 10D cells/50 |xl were 
inoculated subcutaneously into the neck or 1 X 105 cells/ 
200 |xl were injected into the lateral tail vein of C3H/He, 
DBA/2, or other mice, respectively. For quantification of 
lung metastases the animals were killed by cervical dislo-
cation on day 11 or 12. After staining by endotracheal 
infiltration with 15% china ink solution (Rotring Werke 
K G , Hamburg, Germany), lungs were removed, fixed, 
and bleached in Fekete's solution as described [3]. For 
histological detection of lung or liver metastases mice 
were killed on day 4 after tumor inoculation, and the 
livers were removed and fixed in 4% buffered formalin. 
Paraffin sections were cut and stained with haematoxylin-
eosin. Number and diameter of metastases were deter-
mined by analyzing the metastatic foci using a micro-
scope. 
Tumor Cell Adhesion Assay 
CFS-1 cells (5 x 105/ml) in HBSS containing 2 mM 
Ca 2 Cl 2 and 2 mM M g 2 C l 2 and 10 mM Hepes were al-
lowed to bind to bEnd3 endothelioma cells grown in 
Labtek chamber slides. bEnd3 cells were stimulated with 
rmTNF for 4 or 16 hr, respectively. The binding assay 
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Fig. 1. Enhancement of fibrosarcoma CFS-1 colony formation 
in the lungs of animals after treatment with LPS and reversal of 
the metastasis-enhancement by antibodies to TNF. The animals 
received 20 fxg LPS, 40 i±g anti-mTNFmAk V1q, or 100 fxl PBS, 
respectively, i.p., before i.v. application of the tumor cells. The 
number of colonies was determined in histological sections of the 
lungs 4 days after tumor cell application. 
was performed for 60 min at room temperature without 
shaking. The slides were fixed in 2% glutaraldehyde/PBS 
after a brief wash in PBS. Cell binding was measured by 
counting 4 independent 40 x fields by video microscopy 
using IMAGE 1.42 software. The counted area is approx-
imately 0.25 mm 2. 
RESULTS AND DISCUSSION 
Metastasis and Inflammation 
Reports can be found in the literature focusing on the 
fact that inflamed tissue is a favored target of tumor cell 
colonization [9,10]. Enhanced tumor cell colonization to 
the lung was measured when we injected bacterial l i -
popolysaccharide (LPS) into mice 3 hr prior to the iv 
inoculation of tumor cells (Fig. 1). This LPS effect was 
reversed by blocking endogenous TNF production in the 
LPS-injected mice with mouse TNF-neutralizing anti-
bodies, indicating that TNF was a mediator in this me-
tastasis-enhancing effect of LPS. Other investigators 
found inhibition of LPS-enhanced metastasis by using 
IL-Ira [11]. Very clearly, dose-dependently enhanced 
tumor cell colonization to the lungs was observed after 
application of rhTNF, as well as rmTNF with i.v.-in-
jected fibrosarcoma (CFS-1) [3] or with melanoma (B16) 
cells. Also, metastasis to the liver and spleen after i.v. 
injection of the highly metastatic thymoma cells (ESb) 
was enhanced by exogenous TNF (Fig. 2). TNF had to be 
given within 24 hr of tumor cell inoculation to exert its 
metastasis-enhancing effect. 
TNF enhanced metastasis not only in the simplified 
tumor cell colonization model using i.v. tumor cell injec-
tion but also in a model of spontaneous metastasis. Spon-
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Fig. 2. Enhancement of thymoma ESb colony formation in the 
livers of animals after treatment with either 100 p.l PBS (Control) 
or 10 |xg rmTNF i.p. before i.v. application of the tumor cells. The 
number of colonies was determined in histological sections of the 
livers 4 days after tumor cell application. 
taneous liver colonization of ESb thymoma cells originat-
ing from an established tumor was similarly enhanced by 
TNF. In this case, TNF had to be injected at the time 
when individual ESb tumor cells were dislodged from the 
solid primary tumor and found in circulation (day 7) [12] 
(Orosz et al., manuscript submitted). 
Taken together, enhanced metastasis has been ob-
served in several different systems of experimental me-
tastasis with IL-1, TNF, and IFN-7 [1-4.13]. Tumor 
cells were either coinjected with cytokines [1.3] or tumor 
cells stably transfected with cytokine genes were used 
[4,5]. In some of these models even in vitro pretreatment 
of tumor cells with IL-1 or TNF, respectively, enhanced 
colony formation in vivo. When this was tried with 
CFS-1 or ESb with rmTNF as activator in our systems we 
could not detect any significant enhancement of metasta-
sis . This could possibly be explained by the fact that other 
tumor cells were used in the described experiments. In 
the case of Lollini et al. [13] the B16 melanoma cells 
displayed enhanced MHC class I antigen expression after 
exposure to TNF which could possibly have lead to re-
duced NK sensitivity. Such enhanced class I antigen ex-
pression was neither detectable in the CFS-1 nor the ESb 
cells used by us. 
Mechanisms Involved 
in TNF-Enhanced Metastasis 
T-cell responses based on MHC incompatibilities did 
not seem to play a role in the enhancement of colony 
formation by i.v. injected tumor cells. The metastatic 
capacity of C3H-derived fibrosarcomas (CFS-1) differed 
in the tested mouse strains, inducing hardly any lung 
colonies in NMRI animals (Fig. 3). In the other strains 
used, clear differences in the extent of metastasis were 
found with the following hierarchy of metastasis forma-
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Fig. 3. Enhancement of fibrosarcoma CFS-1 colony formation 
in the lungs of mice of different strains after treatment with either 
100 jxl PBS (open bars) or 5 \xg rmTNF (hatched bars) i.p. before 
' i.v. application of the tumor cells. The number of colonies was 
determined in histological sections of the lungs 4 days after tumor 
cell application. 
tion: C3H < C57B1/6 < BalbC. However, in all cases, 
significant stimuation of colony formation was induced 
by the application of TNF independently of the basic 
levels of tumor cell colonization in the respective mouse 
strain (Fig. 3). 
In vitro as well as in vivo some enhanced proliferative 
activity of the tumor cells was found after TNF treatment 
[3]. However, the average size of the lung colonies was 
not different in TNF- versus un-treated mice which indi-
cates that direct growth promoting activity of TNF prob-
ably did not account for the observed enhanced metas-
tasis. 
Participation of the NK Cell System 
NK activity is an important protective mechanism that 
accounts to a large degree for tumor cell destruction in the 
circulation. Since we found enhanced NK activity in 
spleen cells from animals which had been injected i.v. 
with fibrosarcoma cells, impairment of such NK activity 
could explain the enhanced metastasis observed after 
TNF treatment: Indeed, spleen NK activity was reduced 
24 hr after TNF injection supporting the idea of an im-
paired NK system by TNF being the reason for enhanced 
metastasis. However, when NK-deficient mice were used 
for the experiments, the number of metastases in general 
was higher than in normal mice, as had been expected 
and published [14,15]; and, as shown in Figure 4, TNF 
still exerted a metastasis-enhancing effect in these ani-
mals. This made it clear that the enhancing effect of TNF 
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Fig. 4. Enhancement of fibrosarcoma CFS-1 colony formation 
in the lungs of C57BI/6 mice (open bars) or NK-deficient C57BI/6 
beige mice after treatment with either 100 \ú PBS or 1 ^g or 5 fxg 
rmTNF i.p. before i.v. application of the tumor cells. The humber 
of colonies was determined in histological sections of the lungs 4 
days after tumor cell application. 
on metastasis formation was not only due to impairment 
of NK activity. 
Tumor Cell Endothelial Cell Adhesion 
Another facet of the spectrum of TNF activities which 
has to be kept in mind as possibly contributing to the 
enhancement of tumor ceil metastasis is the strengthened 
adhesion of tumor cells to endothelium after TNF expo-
sure. In several in vitro adhesion assays it has been shown 
that pretreatment of endothelial cells with TNF leads to 
enhanced adhesion of tumor cells [16-18]. We also found 
that preexposure of mouse endothelioma cells (bEnd3) 
resulted in a TNF-dose-dependent enhancement of adhe-
sion of ESb and CFS-1 tumor cells (Fig. 5). In the case of 
ESb cells this adhesion was blocked by the addition of 
monoclonal antibodies which interfered with the interac-
tion of VLA-4 on the tumor cells and VCAM-1 on the 
endothelioma cells (Orosz et al., manuscript submitted). 
It remains to be tested whether the VLA-4-VCAM-1 in-
teraction is of importance for formation of spontaneous 
liver metastases by ESb also in vivo. 
Preliminary experiments showed that lung colony for-
mation using the CFS-1 fibrosarcoma cells was abolished 
by the injection of peptides containing the RGD motif, an 
amino acid séquence which is common in extracellular 
matrix proteins and responsible for integrin binding. Sim-
ilarly, it has been published that a TNF fusion protein 
which contains the laminin-specific YIGSR motif on the 
N-terminus did not exhibit enhancement of metastasis 
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Fig. 5. Adhesion of fibrosarcoma CFS-1 tumor cells to TNF-
activatea endothelioma bEnd3 cells. A confluent layer of bEnd3 
cells was exposed to different concentrations of rmTNF for 12 hr 
before the tumor cells were added. Adherent tumor ceils were 
counted after 60 min. 
Fig. 6. Schematic presentation of cells and cell-cell interactions 
possibly affected by TNF during extravasation of tumor cells. 
any longer [19]. This indicates that integrin interactions 
via the fibronectin or laminin receptors are important for 
the observed TNF effect. Experiments utilizing neutraliz-
ing monoclonal antibodies to ICAM-1 or LFA-1 mole-
cules have to be performed in NK-deficient mice in order 
to avoid interference with the TNF-responsive NK sys-
tem. These experiments would discriminate between the 
enhancing effect due to impaired NK activity and the 
metastasis inhibitory effect based on reduced tumor cell 
adhesion: The contribution of other adhesion molecules 
like CD44 [20] or E-selectins [21] for metastasis are well 
documented. Whether these surface structures are also 
involved in the phenomenon of TNF-enhanced metastasis 
has not been tested so far. 
CONCLUSION 
The complex process of metastasis can become af-
fected at many steps by mediators of inflammation. 
TNF and Metastasis 13 
Figure 6 only depicts some of the cells and cell-cell 
interactions which are relevant to the tumor cell extrava-
sation. We have attempted to analyze which steps are 
involved in TNF-enhanced metastasis using different ex-
perimental models. Our findings are in good accordance 
with the literature, indicating that the most important 
mechanism for enhanced metastasis under inflammatory 
conditions seems to be the TNF- or IL-1-increased adhe-
sion of tumor cells to the capillary endothelial cells. 
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